Pharsight

Exforge Hct generic

Exforge Hct is an anti-hypertensive drug made by Novartis. The active ingredients in it are Amlodipine Besylate, Hydrochlorothiazide, and Valsartan. The drug first received market authorization on April 30, 2009.

When will Exforge Hct generic be available?

The Exforge Hct generic could become available after November 16, 2023. This is due to the expiration of the last patent, US8475839*PED on this date.

Exforge Hct uses

Exforge Hct is used to treat high blood pressure. Its active ingredients Amlodipine Besylate, Hydrochlorothiazide, and Valsartan work together to relax the blood vessels, reduce fluid amounts, and decrease blood pressure.

Exforge Hct patent expiration

Exforge Hct has three patents, all of which have expired. The last patent, US8475839*PED, directly impacts the Exforge Hct generic release date and will expire on November 16, 2023. Below are the details of the patent:

EPO Oppostions filed on Exforge Hct

Exforge Hct dosage

Want to ask something?